dWe assessed a novel immunochromatographic lateral flow assay for direct identification of OXA-48-like carbapenemases and accurate differentiation of allele variants with distinct substrate profiles (OXA-48 or OXA-163 subfamilies). The assay allowed rapid (less than 4 min) and reliable direct confirmation of OXA-163-and/or OXA-48-like enzymes (with 100% sensitivity and 100% specificity) from cultured colonies that were recovered from both solid medium and spiked blood culture bottles.
The emergence and spread of Enterobacteriaceae that produce plasmids encoding class A (KPC, GES, Sme, NMC-A), B (IMP, VIM, NDM), and D (OXA-48-like) carbapenemases are worldwide public health threats. To prevent the spread of carbapenemase producers and define an appropriate empirical antimicrobial therapy, the rapid detection of carbapenemase-producing organisms has become imperative (1). One of the major concerns for controlling the spread of OXA-48-like producers is the absence of reliable phenotypical tests that might contribute to their easy recognition. This is due in part to relatively low carbapenem MICs, a lack of suitable inhibitor compounds for use in confirmatory tests, and the very low expression of carbapenemase activity which cannot be detected readily by recently developed biochemical methods (1-5). Recently, a novel means of detecting OXA-48-like enzymes via an antibody-mediated approach was developed (6). The OXA-48 K-SeT test (Coris BioConcept, Belgium) relies on immunological capture of two epitopes specific to the OXA-48 variants OXA-48, OXA-181, OXA-204, OXA-232, and OXA-244 using colloidal gold nanoparticles bound to a nitrocellulose membrane within a lateral flow device (6). The reported sensitivity and specificity were both 100%, with the result obtained in less than 10 min (6-10). Noteworthy is that new allelic variants of OXA-48 have emerged, namely, OXA-163 and the related variants OXA-247, , which are not recognized by the OXA-48 K-SeT test (6,8,10). OXA-163, which is the only variant of this subfamily that has spread to several hospitals in Argentina and Egypt (15, 16), differs from OXA-48 by a single amino acid substitution and a four-amino-acid deletion. In earlier studies, OXA-163 exhibited almost undetectable carbapenemase activity with a substrate profile that included broad-spectrum cephalosporins (11). However, recent reports indicate that this allele might produce enhanced carbapenemase activity in the presence of carbonates (13, 17), suggesting that its activity is strongly influenced by the rate of carboxylation of the active site, as observed for other carbapenem-hydrolyzing class D -lactamases (18,19). Additionally, in vivo data suggested that OXA-163 might cause carbapenem treatment failures in critically ill patients (12,15,20) or favor intrapatient selection of new OXA-48 variants (12), which highlights the urgent need for efficient identification tests.Definitive confirmation of OXA-163-and/or OXA-48-like producers currently relies on molecular assays and gene sequencing for the assign...